161 related articles for article (PubMed ID: 32770971)
1. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy.
Li C; Lu F; Lei T; Yu H; Chen X; Peng S; Han S; Yang H
BMC Cancer; 2020 Aug; 20(1):742. PubMed ID: 32770971
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.
Liu C; Zhang X; Zhu Y; Wei J; Ye X; Yang C; Tong H; Mai W; Yang M; Qian J; Mao L; Meng H; Jin J; Yu W
Ann Hematol; 2023 Sep; 102(9):2387-2395. PubMed ID: 37278748
[TBL] [Abstract][Full Text] [Related]
3. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
5. Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients.
Li C; Lu F; Lei T; Yu H; Yang H
Transl Cancer Res; 2020 Sep; 9(9):5139-5146. PubMed ID: 35117880
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic antibiotics for the prevention of early infection in multiple myeloma.
Oken MM; Pomeroy C; Weisdorf D; Bennett JM
Am J Med; 1996 Jun; 100(6):624-8. PubMed ID: 8678082
[TBL] [Abstract][Full Text] [Related]
7. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
9. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
10. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Kurokawa T; Kaya H; Yoshida T
J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
[TBL] [Abstract][Full Text] [Related]
11. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
[No Abstract] [Full Text] [Related]
12. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
[TBL] [Abstract][Full Text] [Related]
14. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
Salmasi G; Li M; Sivabalasundaram V; Panzarella T; Tsang R; Kukreti V; Crump M; Kuruvilla J
Leuk Lymphoma; 2015 Jun; 56(6):1659-64. PubMed ID: 25356925
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Park JW; Curtis JR; Kim MJ; Lee H; Song YW; Lee EB
Arthritis Res Ther; 2019 Sep; 21(1):207. PubMed ID: 31521185
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Zettl F; Ziepert M; Altmann B; Zeynalova S; Held G; Pöschel V; Hohloch K; Wulf GG; Glass B; Schmitz N; Loeffler M; Trümper L
Ann Hematol; 2021 Apr; 100(4):1031-1038. PubMed ID: 33242101
[TBL] [Abstract][Full Text] [Related]
18. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
19. Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival.
Wei W; Zhu Y; Tang J; Xu C; Li J; He S; Zhang Z; Wu P; Luo L; Guo Q; Li F; Ren Y; Yu S; Li R; Li L
Leuk Res; 2021 Dec; 111():106688. PubMed ID: 34450501
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
